sequenti improv
organ sale growth drive
colgat post acceler organ sale growth albeit
still trail large-cap peer guid
improv although margin disappoint
seemingli due transitori item
improv organ sale growth cl stock post ep
 third consecut quarter sequenti organ
sale growth improv y-o-i vs
first three quarter also note cl gm return
expans bp y-o-i bp consensu first time sinc
oper profit miss consensu higher sg cl
highlight call sg increas temporari natur
due higher compens logist cost cycl one-tim benefit
year ago period encourag sequenti top-line
improv note mainli driven easier comparison
averag organ sale growth although
convinc cl remain msd
growth rate larg cap peer post comparison becom
difficult colgat cycl strong innov pipelin colgat total
sf hill scienc diet remain ew market seem price
sustain top-line turnaround cl trade price-to-earnings
premium ko premium mega-cap peer ko/pep/pg despit
uncertain top-line growth outlook clearli prefer ko lower
valuat level superior lt top-line growth outlook detail
see ko upgrad recent webcast replay slide show
estim back quarter ytd number bp
yoy drop global toothpast share bp global toothbrush well
bp respect us toothpaste/toothbrush year-to-d cl
market share yoy region toothpast toothbrush
household person unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
exhibit cl total compani em ltm organ sale
start rebound
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
except flat africa/eurasia toothpast share continu share loss
worrisom although colgat posit new colgat total innov
call note colgat gain market share pet busi
detail call call cl optimist tone
oral care market share result suggest indic pleas satisfi
acceler organ sale growth continu focu
three key strateg prioriti drive growth innov core
busi expand adjac higher growth segment increas
avail higher growth channel innov cl indic colgat
total market share bp global re-launch allow cl take
result us colgat total market share bp yoy
albeit futur benefit come downsiz packag creat quicker
consum replenish cl also sound optimist hill scienc diet
relaunch market share gain us brick-and-mortar on-line
intern roll-out begin term expans
adjac segment cl pleas progress charcoal
natur launch around world expans elmex meridol
brand regard channel expans cl highlight strong growth e-
commerc busi colgat market share bp yoy split
colgat palmol cl commentari around em trend mix
asia grow well outsid china strong acceler africa russia
eurasia cautiou view latin america particularli brazil
mexico econom polit chang china remain drag cl
result cl comment declin line intern
expect busi slightli ahead term expect
turnaround brazil cl categori slightli yoy
improv vs declin last year continu competit promot
environ particularli lower price point cl volum
brazil price strong cl expect improv balanc
year comparison get easier particularli last year trucker
strike cl sound pleas colgat total re-launch brazil
mexico market share bp respect
filorga acquisit skin strategi call cl discuss recent
announc acquisit laboratoir filorga cosmtiqu filorga skin
busi repres ev/sal base last-twelve-
month sale busi gener sale ltm end june
cl indic attract growth profil oper margin
cl person care margin cl expect acquisit neutral ep
cent accret cl sound optimist prospect
acquir busi sale mix anti-ag product one
fastest grow sub-seg skin care high exposur pharmaci
channel opportun expand brand asia well strengthen
posit europ overal acquir busi gross/oper
margin accret acquisit follow prior acquisit pca skin
eltamd profession skin care confirm cl aspir expand
attract skin care categori cl sound excit opportun
expand skin care categori attract characterist includ
high growth rate global high margin worri competit
elev skin care sever scale pure-play beauti compani
lauder oreal better posit success
number cl ep in-lin consensu
estim mse organ top-line gross margin beat off-set
higher sg cl organ sale growth un-round volum
price ahead street account consensu mse
aid easi comparison two-year averag organ sale
growth although
organ sale growth improv emerg market
acceler vs
report sale miss higher fx headwind off-set better
expect gross margin gm bp consensu bp yoy
translat gross profit beat total sg bp
consensu sale higher compens logist cost cycl
one-tim benefit year ago period despit bp
model sale although bp y-o-i sale
sale yoy everi divis drove oper profit miss
vs consensu oper profit line lower tax rate cent
benefit vs model result in-lin ep vs consensu
y-o-i
organ sale growth divis north america organ sale grew y-o-i
vs consensu mse latin america vs
consensu mse volum growth mexico colombia partial
off-set volum declin brazil europ vs consensu
mse asia pacif vs consensu mse
volum declin greater china region partial off-set volum growth
thailand africa/eurasia vs consensu mse behind
volum gain russia gulf state partial off-set volum declin
south africa saudi arabia pet nutrit organ sale growth vs
consensu mse develop market organ sale grew
y-o-i versu y-o-i growth emerg market
ep guidanc reiter toward higher end organ sale
growth cl reiter ep guidanc -msd declin impli
ep assum declin base vs prior consensu
cl expect toward higher end organ sale
guidanc y-o-i still flat lsd report basi greater
vs cl also continu plan year gross margin
expans increas advertis invest call cl lower
tax rate guidanc vs prior indic share
repurchas lower last year level compani
focus pay increment debt filorga acquisit note
guidanc exclud recent filorga skin care acquisit cl expect
neutral ep cent accret
ew net post ep ep unchang higher organ
top-line growth lower tax rate off-set higher fx headwind lower
share repurchas ep move reflect
higher sale base accret filorga acquisit pt
move base ep vs prior higher
base case scenario
organ top-line drive multipl expans bp volum upsid
share gain bp price upsid drive multipl expans
bull case ep includ strateg halo
top-line growth rang forecast organ top-line
growth beyond appli price-to-earnings multipl
line multipl appli pg given strateg potenti cl
sale growth deceler flattish rang secular us pressur drive bp
price downsid bp volum loss bp reinvest
spur top-line weak macro difficult competit environ drive
bp volum bp price invest intern appli
exhibit bear bull top-line upside/downsid driver cl multipl
valu
trend expect organ sale growth
remain rang
beyond cl msd histor trend
low end cl lt target
believ cl organ sale growth
emerg market return
histor level due heighten
competit local player competit
environ compani shift spend
secularli challeng us market
well lower inflationari price compar
last year
diminish strateg still
believ cl advantag vs peer
greater mix higher growth emerg
market person care product
categori believ market
attribut lower strateg halo
histor given weaken
fundament compar histor trend
note knowledg
valuat premium mega-cap peer
growth outlook cl diminish
strateg halo particularli believ cl
price-to-earnings premium ko look high
outlook
risk achiev price
market share payback ad spend
cost consolid potenti increas
downsid risk weaker price
market share loss local player
higher commod cost strateg
sale
sale
sale bp chang
sale
sale bp chang
sale
sale bp chang
note loan payabl
current portion long-term debt
depreci amort
chang a/l
a/p accrual
non-curr asset liabil
provid oper
flow invest activ
sale purchas market secur
payment acquisit
use invest activ
flow financ activit
net payments/proce debt
purchas treasuri share
use financ activ
provid discontinu oper
exchang rate effect
net increas decreas equiv
equiv beg
equiv end
pt forecast organ top-line growth hsd ep growth
beyond appli price-to-earnings multipl base case ep cpg peer
driven strong price power ko transform higher growth/roic
concentr model bottl divestitur posit chang new
volatil health well pressur lower expect product soda
pt forecast organ sale growth go forward
hpc peer led improv us result build market share momentum better
price realiz continu cost save support bp om expansion/yr
drive hsd ep growth appli multipl ep slight premium
pg average given acceler fundament
share vacil currenc commod volatil
pt organ sale growth driven solid snack growth
om expand bp annual post reinvest cost save assum
price-to-earnings cpg peer reflect higher top-line growth visibl
risk lower expect return reinvest
russia/mexico/china volatil commod cost fx volatil lower
expect cost save restructur acceler competit intens
beverag soda tax macro and/or health-rel top-line weak
